GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes. For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online July 14 in the Annals of Internal Medicine.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online July 14 in the Annals of Internal Medicine.
- Ponto de atenção: receptor.
- Ponto de atenção: agonist.
- Ponto de atenção: does.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/a2754d1c-f100-49c9-8370-372612b6b312.jpeg)